Boston Scientific to acquire Penumbra in about $14.5 billion medtech deal

Boston Scientific has agreed to buy Penumbra in a transaction that values the thrombectomy specialist at about $14.5 billion, signaling a major consolidation move in cardiovascular and neurovascular devices. The deal offers Penumbra shareholders $374 a share in cash or 3.8721 Boston Scientific shares per Penumbra share, with the companies expecting a pro-rated mix of roughly 73 percent cash and 27 percent stock.

The acquisition expands Boston Scientific’s portfolio into fast-growing vascular segments, notably stroke and pulmonary embolism treatments, by folding Penumbra’s mechanical thrombectomy products, including the Indigo Aspiration System, into its commercial and R&D platform. Penumbra, led by chairman and CEO Adam Elsesser, was forecast to generate about $1.4 billion in sales in 2025. Penumbra’s chief executive is expected to join Boston Scientific’s board after the deal closes. Boston Scientific chairman and CEO Mike Mahoney said the acquisition gives the company “an opportunity to enter new, fast‑growing segments within the vascular space.”

Market reaction was immediate: Penumbra shares jumped about 12 percent on the announcement, and the price represents a roughly 19.3 percent premium to Penumbra’s last close before the deal was disclosed. Shareholders will be able to elect cash or stock, subject to the final proration. Boston Scientific will fund roughly $11 billion of the cash consideration with a mix of cash on hand and new debt, a financing plan that raises questions about leverage and near-term earnings.

Management said the transaction will likely reduce Boston Scientific’s adjusted earnings per share by $0.06 to $0.08 in the first full year after closing. Analysts and market watchers have flagged financing and integration risks: the planned debt increases interest costs and creates near-term EPS dilution, while successful integration will be required to restore earnings growth and realize projected synergies.

Regulatory scrutiny is likely to be intense. U.S. antitrust authorities are expected to examine overlaps between Boston Scientific’s existing thrombectomy and peripheral intervention assets, particularly its WOLF Thrombectomy platform, and Penumbra’s Indigo system. Antitrust experts warn the Federal Trade Commission could require divestitures or structural remedies to preserve competition, a prospect underscored by recent regulatory precedent such as the blocked acquisition of JenaValve by Edwards Lifesciences. The companies project a regulatory review and integration process that will be critical to closing, with both firms targeting completion in 2026 and the first half of the year flagged as a key window.

Strategically, the deal reflects a broader industry trend toward consolidation as large device makers seek scale in specialized, high-growth clinical areas. For Boston Scientific, the acquisition re-enters and strengthens its neurovascular position while broadening heart and peripheral vascular device offerings. For competitors and payers, it may reshape product portfolios and negotiating leverage in thrombectomy and peripheral intervention markets, depending on whether remedies are required.

Execution risks, the final terms of any regulator-imposed remedies, and the company’s ability to manage higher leverage will determine whether the transaction delivers the revenue growth and market penetration Boston Scientific projects. The headline deal immediately alters the competitive landscape in vascular devices, but its ultimate impact will hinge on regulatory outcomes and the firms’ integration discipline.